New Nymox Second-Hand Smoke Study Begins for NicAlert.
MAYWOOD, N.J.--(BUSINESS WIRE)--Aug. 20, 2002
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a large new prospective study of its NicAlert(TM) test for tobacco exposure has begun at West Virginia University. The investigation is being led by Dr. Norman Montalto.
Dr. Montalto is Associate Professor in the Department of Family Medicine at West Virginia University. He has been actively involved for over a decade in pharmaceutical and tobacco product addiction research, smoking cessation, and clinical trials. Dr. Montalto has numerous peer-reviewed publications in the field, and has served as expert speaker, reviewer and consultant for major pharmaceutical companies that specialize in cessation products. Dr. Montalto is Director of the Freedom From Tobacco Program at the Charleston Area Medical Center and Physician Advisor for Tobacco Cessation Benefit Programs for Medicaid, the Public Employees Insurance Agency (PEIA), and the Medical Director of the State Tobacco Quit-Line.
Second-hand smoke or environmental tobacco smoke (ETS) is increasingly being recognized around the world as a serious but preventable public health risk. Second-hand smoke has been linked to cancer and to increased risk of heart disease and stroke.
NicAlert(TM) is Nymox's simple-to-use test for the determination of tobacco use or exposure. It uses either urine or saliva samples to detect levels tobacco exposure for smokers and non-smokers. NicAlert(TM) is currently being used in research programs into tobacco used and exposure and is being marketed in the United States and Japan as a test to determine whether a person, such as a teenager, student, athlete or insurance applicant is using a tobacco product.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.